New York, Jan 15, 2026, 13:24 EST — Regular session
- Big drugmakers are once again zeroing in on vaccine demand sentiment
- Competition in obesity drugs stays intense as firms race to develop GLP-1 pills
- Traders are gearing up ahead of Pfizer’s upcoming quarterly report
Pfizer shares edged up roughly 0.3% to $25.67 on Thursday, finding footing after a volatile start to the year. Investors mulled over renewed discussions on U.S. vaccine policy alongside Pfizer’s growth strategy. The stock fluctuated between $25.26 and $25.67, with about 22.3 million shares changing hands.
Why it matters now: vaccine makers face fresh political and demand challenges in the U.S. Sanofi CEO Paul Hudson warned of near-term “softness” in vaccine uptake, blaming “misinformation.” Pfizer CEO Albert Bourla expressed being “seriously frustrated,” labeling the trend as “political and antivax,” Reuters reported. Reuters
Pfizer’s earnings schedule dovetails with a crucial earnings cycle that will shape its 2026 spending and margins. The company plans to release its Q4 corporate performance update on Feb. 3.
Pfizer’s latest guidance projects 2026 revenue between $59.5 billion and $62.5 billion, with adjusted diluted EPS ranging from $2.80 to $3.00—this measure excludes certain items. The company also warned of a drop in COVID-19 product sales compared to last year, alongside headwinds from products losing exclusivity, meaning key patents and protections will expire.
Structure Therapeutics CEO Raymond Stevens told Reuters that oral weight-loss pills could claim up to half of the GLP-1 market by 2030 — a sector now dominated by GLP-1 drugs, which mimic a gut hormone and are key in treating obesity and diabetes. He estimated the market’s potential at $150 billion. Stevens also highlighted mounting dealmaking pressure in the space; Pfizer snapped up obesity drugmaker Metsera for $10 billion last November, Reuters reported.
Another angle gaining traction involves drug discovery fueled by artificial intelligence, though its day-to-day valuation remains tricky. On Thursday, Reuters highlighted several AI-linked collaborations in pharma, notably Pfizer’s expanded partnership with PostEra to accelerate drug design processes.
The policy environment remains critical since vaccines continue to be a key part of Pfizer’s business beyond the post-pandemic shift. A prolonged decline in U.S. vaccine demand would strain the company just as it works to revitalize growth in other areas.
The upside, however, isn’t straightforward. Should vaccine demand weaken beyond forecasts or if late-stage obesity and oncology projects don’t lead to approvals and product launches, investors might remain focused on immediate earnings instead of the long-term pipeline potential.
Pfizer climbed 1.7% on Wednesday, ending a two-day slide. Still, it underperformed several rivals during a generally down day for the broader market, MarketWatch reported.
Investors are keen to hear how Pfizer intends to juggle R&D expenses alongside cost-cutting measures. They’ll also be watching for any early indications from management about vaccine skepticism affecting orders and uptake in the U.S.
Pfizer’s upcoming fourth-quarter earnings report and conference call on Feb. 3 will be a key event, with the company set to outline its 2026 outlook and strategic priorities.
